Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Gastrointestinal Motility Disorders

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...

Irritable Bowel Syndrome III: Medical and Nursing Management

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pediatric Inguinal Hernia Repair with Laparoscopy (PIHRL)-trial: A multicenter study comparing extra-corporeal Percutaneous Internal Ring Suturing (PIRS) and intra-corporeal purse-string suture for inguinal hernia.

Journal of pediatric surgery·2025

Same author

Chorioamnionitis induces enteric nervous system injury: effects of timing and inflammation in the ovine fetus.

Molecular medicine (Cambridge, Mass.)·2020

Same author

Editor's Choice - Nationwide Analysis of Patients Undergoing Iliac Artery Aneurysm Repair in the Netherlands.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2020

Same author

Long-term functional outcomes and quality of life in patients with Hirschsprung's disease.

The British journal of surgery·2019

Same author

Cost-effectiveness of sacral neuromodulation for chronic refractory constipation in children and adolescents: a Markov model analysis.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2017

Same author

Randomized clinical trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in patients with faecal incontinence.

The British journal of surgery·2017

Same journal

Needle-based confocal laser endomicroscopy and artificial intelligence in pancreatic cystic lesions: Insights and clinical advances.

Best practice & research. Clinical gastroenterology·2026

Same journal

Evidence-based approach to the diagnosis, management and surveillance of pancreatic cystic lesions: from the guidelines to the clinical practice.

Best practice & research. Clinical gastroenterology·2026

Same journal

Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound.

Best practice & research. Clinical gastroenterology·2026

Same journal

Predictive risk models for the diagnosis and cancer progression of pancreatic cysts.

Best practice & research. Clinical gastroenterology·2026

Same journal

Preface.

Best practice & research. Clinical gastroenterology·2026

Same journal

Endoscopic ultrasound-guided treatment of pancreatic lesions.

Best practice & research. Clinical gastroenterology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Published on: July 26, 2024

Neuromodulation for functional bowel disorders.

B Govaert¹, W G van Gemert, C G M I Baeten

¹Maastricht University Medical Centre, Department of Surgery, Postal Box 5800, 6202 AZ Maastricht, The Netherlands.

Best Practice & Research. Clinical Gastroenterology

|August 4, 2009

Summary

This summary is machine-generated.

Sacral nerve neuromodulation (SNM) offers a minimally invasive treatment option for functional bowel disorders, including fecal incontinence and constipation. A temporary screening phase helps assess suitability for this evolving therapy.

More Related Videos

Gastrointestinal Motility Monitor (GIMM)

Gastrointestinal Motility Monitor (GIMM)

Published on: December 1, 2010

Related Experiment Videos

Last Updated: Jun 21, 2026

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Using An In Vitro Tissue Perfusion System to Detect the Functional Activities of Isolated Intestinal Tubes in Real Time

Published on: July 26, 2024

Gastrointestinal Motility Monitor (GIMM)

Gastrointestinal Motility Monitor (GIMM)

Published on: December 1, 2010

Area of Science:

Gastroenterology and Neurology
Pelvic floor dysfunction treatment

Background:

Functional bowel disorders unresponsive to conventional therapies pose a clinical challenge.
Sacral nerve neuromodulation (SNM) has emerged as a treatment for fecal incontinence and constipation.
The precise mechanisms of SNM action are not fully elucidated but involve direct anal sphincter stimulation and altered rectal sensation.

Purpose of the Study:

To review the current applications and outcomes of sacral nerve neuromodulation (SNM) for functional bowel disorders.
To highlight the role of the temporary screening phase in patient selection for SNM therapy.
To discuss emerging indications for SNM in anorectal and pelvic conditions.

Main Methods:

Review of existing literature on sacral nerve neuromodulation (SNM) for functional bowel disorders.
Emphasis on the temporary screening phase as the primary method for assessing treatment candidacy.
Discussion of clinical outcomes and evolving techniques in SNM therapy.

Main Results:

Sacral nerve neuromodulation (SNM) demonstrates good clinical results for functional bowel disorders.
The temporary screening phase remains the preferred method for evaluating potential SNM candidates.
Ongoing technical advancements are associated with a reduction in SNM-related complications.

Conclusions:

Sacral nerve neuromodulation (SNM) is a viable treatment for refractory functional bowel disorders.
The temporary screening phase is crucial for optimizing patient selection and outcomes.
Expanding indications for SNM include constipation, anorectal pain, and pelvic pain.